Med by Cell Press的动态

??? New episode alert! Join Dr Stephanie Gall, Prof Marina Anderson, and Dr Sarah Tansley as they dive into interpreting antibody results for systemic sclerosis, myositis, and overlaps. Learn about clinical patterns AND spotting false positives. ???????? https://bit.ly/3CA33L9

??First day of #EULAR2024 ??Join me today at the Clinical Abstracts Session: clinical aspects of SSc ??Room A7 ?5 pm ??The role of inflammation in SSc: CRP-associated phenotypes and prognostic implications @EUSTAR_org @JOVREUM @EMEUNET @ReumaLeon

The #Duchenne and #Becker journeys are complex, but PPMD is here for you. Whether you have follow-up questions coming out of our 30th Annual Conference, have just received a diagnosis, or are looking for information about genetics and clinical trials, navigating school and IEPs, or planning for independent living, we’re here to provide you with resources to help you navigate the concerns and decisions that are part of Duchenne and Becker. Through the PPMD For You program, you can schedule a one-to-one meeting with an expert member of the PPMD team for personalized support. https://lnkd.in/eyST7M3B

Two weeks left to ensure your research gets the attention it deserves! Submit your late-breaking abstract for #IPVC2024 by September 1, 2024, and share your findings with the international papillomavirus community. Oral and poster presentation slots have been kept for the best late-breakers. Why Submit? ?? Reach a diverse global audience of professionals ?? Gain valuable exposure and feedback from experts ?? Make a meaningful impact on the #HPV field Submit now ?? https://lnkd.in/dfRAs58 #PapillomavirusResearch #cervicalcancer #cancerresearch #womenshealth

Please help us welcome our keynote speaker, Sammy Basso! Sammy was diagnosed with Progeria when he was two year-old. Now he is 28, and chose to be a scientist for studying is own disease. As a researcher and patient advocate, he will talk about the 25 years of science that is working now for a genetic cure and the pivotal role that families and patient had and are having on it. Don't miss this inspiring talk, please register for the conference: https://lnkd.in/dQMUdD_Y #mitochondrialdisease #leighsyndrome

Sure, Sora's cool, but have you tried Nightlight? https://lnkd.in/gAUmXPdA Nightlight is a SOTA model, built by Alex Abbey?at Lodestar to do novel target discovery for rare diseases. This video walks through using Nightlight to compare two sets of HPO terms to measure similarity.? Nightlight gets more interesting when you scale up the number of comparisons. We’ve used this model to explore: ?? Clinical trial recruitment ?? Genotype prediction ??? HPO term prompting Anvil's free compute is limited, so if you're curious about using Nightlight beyond the demo, please message me or Alex! https://lnkd.in/gAUmXPdA

?? New Data on REBOA: Partial vs Complete – Which is Better? ?? From EVTM a recent study from the AAST AORTA registry challenges preclinical expectations, showing no significant differences in mortality or complications between partial and complete REBOA in trauma patients. But the debate isn’t over yet! ?? Incomplete data and the need for larger sample sizes make it hard to draw definitive conclusions. What will future studies reveal? ?? Learn more about REBOA’s effectiveness in trauma care and what’s needed to unlock its true potential! https://lnkd.in/drDdz-A2

?? The MASH CALL Initiative – back by popular demand this ?? September We at InSphero believe that there is a way to ?? #stopMASH, by joining forces with researchers and looking into new ways to investigate this unmet clinical need. After the successful first MASH CALL Initiative, we are launching a second round this ?? September: ???? Is your research related to the complex, multi-faceted #liverdisease? ?? Would you like to be at the forefront of finding an effective therapy, which will help over 115 million individuals worldwide? Within the MASH CALL Initiative, you will get valuable insights about the effects of your compounds related to: ?? anti-steatosis ?? anti-fibrosis ?? safety profile ?? comparison to clinical candidates ?? Want to learn more? Click on the link in the comments and read the latest blog post by Dr. Francisco Verdeguer, VP of Liver Disease, who sheds light on the learnings from the first initiative and shares insights on the approach of the MASH CALL work-frame. ? Francisco Verdeguer Radina Kostadinova, PhD Jesus Francisco Glaus Garzon Angelina Freitag Joel Zvick Philip Vonschallen Paul Edgard Clémen?on Arumugham (Ragoo) Raghunathan B?rbel Ulmer Christine Schwenk Sue Grepper, PhD Madhu Lal Nag, MBS PhD Jan Lichtenberg Rositsa Hadzhipetrova Tina ?el PharmaNest Mathieu Petitjean #mashcallinitiative #liverdisease #mash #masld #3dcellculture #3dhumanliver #mashscreening

Part of Secondary Prevention in my eyes = Early accurate Multi-organ Clinical assessment (Opportunity) & Diagnostics ... to enable Early and efficacious Multi-organ Disease Management...

Please join me to discuss some interim data from VERDICT, designed to determine the optimal treatment target ?? in people living with #ulcerativecolitis. This has been a huge global effort to randomize 660 subjects living with Ulcerative colitis. Now we are in the 2 year follow up period with topline results scheduled for 2026. #IBD #clinicaltrials #drugdevelopment #clinicalresearch